Video

Peter Chin, MD

Publish date: July 18, 2016

Dr. Chin discusses the results of several studies presented at the 2016 Annual Meeting of the CMSC that relate to ocrelizumab.


 

References

The video associated with this article is no longer available on this site. Please view all of our videos on the MDedge YouTube channel.

Recommended Reading

Teriflunomide effective for faster-advancing MS
ICYMI Multiple Sclerosis
Real-world data favor dimethyl fumarate, fingolimod for MS
ICYMI Multiple Sclerosis
Exercise improves sleep and may improve cognitive/physical function in MS
ICYMI Multiple Sclerosis
Alemtuzumab beneficial for MS patients of African descent
ICYMI Multiple Sclerosis
Real-world MS relapse rate is low for dimethyl fumarate
ICYMI Multiple Sclerosis
Frederick Munschauer, MD
ICYMI Multiple Sclerosis
Choosing MS Treatments From the Therapeutic Armamentarium
ICYMI Multiple Sclerosis
Ocrelizumab May Be More Effective for Relapsing-Remitting MS Than Interferon
ICYMI Multiple Sclerosis
Can Stem Cells Halt Progression of MS?
ICYMI Multiple Sclerosis
Siponimod shows promise through 24 months in relapsing-remitting MS
ICYMI Multiple Sclerosis